March 14, 2011 12:20pm EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE Amex:OPK) today announced the completion of a
public offering of 27,000,000 shares of its common stock at a price to
the public of $3.75 per share, before underwriting discounts and
commissions. The Company has granted the underwriters a 30-day option to
purchase up to an additional 4,050,000 shares of common stock. All of
the shares were offered by the Company.
The Company anticipates using the net proceeds of the offering for
general corporate purposes, including research and development expenses,
clinical trials, acquisitions of new technologies or businesses, and
other business opportunities.
Jefferies & Company, Inc. and J.P. Morgan Securities LLC acted as joint
book-running managers for the offering. UBS Investment Bank and Lazard
Capital Markets LLC acted as co-lead managers for the offering and
Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann
Financial Services Inc. (NYSE Amex:LTS), acted as co-manager for the
offering.
The securities described above were offered by the Company pursuant to a
shelf registration statement previously filed with and declared
effective by the U.S. Securities and Exchange Commission (the "SEC"). A
final prospectus supplement related to the offering has been filed with
the SEC and is available on the SEC's website located at http://www.sec.gov .
Copies of the final prospectus supplement related to these securities
may be obtained from the Equity Syndicate Prospectus Department,
Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY,
10022, at 877-547-6340, and at Prospectus_Department@Jefferies.com ,
or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717 or by calling
1-866-803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About OPKO Health, Inc.
We are a multi-national pharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large and rapidly
growing medical markets by leveraging our discovery, development and
commercialization expertise and our novel and proprietary technologies.
Our current focus is on conditions with major unmet medical needs
including neurological disorders, infectious diseases, oncology and
ophthalmologic diseases.
Certain of the statements made in this press release are
"forward-looking statements," as that term is defined under the Private
Securities Litigation Reform Act of 1995 (PSLRA), which statements may
be identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "could," "intends,"
"estimates," and other words of similar meaning, including statements
regarding our offering of shares of common stock and the expected use of
proceeds of such offering. Many factors, including those described in
our filings with the Securities and Exchange Commission, could cause
actual results or developments to differ materially from those projected
or implied in these forward-looking statements. In addition,
forward-looking statements may also be adversely affected by risks
inherent in funding, developing and obtaining regulatory approvals of
new, commercially-viable and competitive products and treatments,
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The Company will continue to need significant amounts of
additional capital to fund its operations and may be unable to raise
capital when needed, which would force the Company to delay, reduce the
scope of or eliminate one or more of its development programs.
Additional risks and uncertainties relating to the offering, the Company
and its business can be found under the heading "Risk Factors" in the
final prospectus supplement related to the offering filed with the
Securities and Exchange Commission. The Company disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Source: OPKO Health, Inc.
Released March 14, 2011
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page